Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy

Oncogenic KRAS is found in >25% of lung adenocarcinomas, the major histologic subtype of non-small cell lung cancer (NSCLC), and is an important target for drug development. To this end, we generated four NSCLC lines with stable knockdown selective for oncogenic KRAS. As expected, stable knockdow...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Sunaga, Noriaki, Shames, David S., Girard, Luc, Peyton, Michael, Larsen, Jill E., Imai, Hisao, Soh, Junichi, Sato, Mitsuo, Yanagitani, Noriko, Kaira, Kyoichi, Xie, Yang, Gazdar, Adi F., Mori, Masatomo, Minna, John D.
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3061393/
https://ncbi.nlm.nih.gov/pubmed/21306997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-10-0750
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars